摘要
过敏性鼻炎和哮喘的发病率逐年上升,目前的治疗以药物控制症状为主,少部分患者接受变应原特异性免疫治疗。随着分子生物学、免疫学和遗传学等相关学科的发展,近年来已有基础和临床研究对呼吸道变态反应性疾病的新疗法进行了有益的探索,力求寻找新的靶点和途径,包括基因重组疫苗、抗IgE抗体、抗细胞因子、干预转录因子的基因表达、反义治疗和RNA干扰等,以从多方面阻断呼吸道变态反应性疾病的发生和发展。
The prevalence of allergic rhinitis and asthma increased over the last few decades.Current therapeutics is mainly confined to symptom controlling by pharmacological treatment, with only a small proportion of patients under the treatment of allergen-specific immunotherapy.Recently, based on the development of molecular biology, immunology, genetics and the related sciences, basic and clinical studies have been conducted successfully in new therapeutics of allergic airway diseases, including genetic recombinant vaccine, anti-IgE antibody, anti-cytokine, interference in gene expression of transcription factors, antisense therapy and RNAi, in order to explore novel methods and approaches for blocking the initiation of disease.This review summarized the research advances in new therapeutics for allergic rhinitis and asthma.
出处
《中华临床免疫和变态反应杂志》
2010年第2期124-130,共7页
Chinese Journal of Allergy & Clinical Immunology
基金
教育部留学回国人员科研启动基金(教外司留2008-890)
江苏省"科教兴卫工程"医学重点学科(XK200719)和重点人才(RC2007065)基金
